OBJECTIVE: We evaluated the hypothesis that ovarian cancer patients have significantly higher levels of serum macrophage migration inhibitory factor (MIF). STUDY DESIGN: MIF levels were determined by enzyme-linked immunosorbent assay (ELISA) in epithelial ovarian cancer cell lines and immortalized normal ovarian surface epithelial cells and in serum of ovarian cancer patients (n = 54) and age-matched healthy women (n = 60). To determine the impact of Toll-like receptor-4 ligation on MIF levels, cells were treated for 48 hours with lipopolysaccharide. RESULTS: Cancer cells, but not normal cells, secrete significant amounts of MIF. This correlates in vivo, where serum MIF levels are significantly higher in ovarian cancer patients. Treatment of cancer cells with lipopolysaccharide induced a significant increase in MIF secretion. CONCLUSION: MIF may be relevant in the process of ovarian cancer formation and progression. The events leading to the induction of MIF expression and its contribution to ovarian cancer progression may open new venues for targeted therapy.
OBJECTIVE: We evaluated the hypothesis that ovarian cancerpatients have significantly higher levels of serum macrophage migration inhibitory factor (MIF). STUDY DESIGN:MIF levels were determined by enzyme-linked immunosorbent assay (ELISA) in epithelial ovarian cancer cell lines and immortalized normal ovarian surface epithelial cells and in serum of ovarian cancerpatients (n = 54) and age-matched healthy women (n = 60). To determine the impact of Toll-like receptor-4 ligation on MIF levels, cells were treated for 48 hours with lipopolysaccharide. RESULTS:Cancer cells, but not normal cells, secrete significant amounts of MIF. This correlates in vivo, where serum MIF levels are significantly higher in ovarian cancerpatients. Treatment of cancer cells with lipopolysaccharide induced a significant increase in MIF secretion. CONCLUSION:MIF may be relevant in the process of ovarian cancer formation and progression. The events leading to the induction of MIF expression and its contribution to ovarian cancer progression may open new venues for targeted therapy.
Authors: Olivia Twu; Daniele Dessí; Anh Vu; Frances Mercer; Grant C Stevens; Natalia de Miguel; Paola Rappelli; Anna Rita Cocco; Robert T Clubb; Pier Luigi Fiori; Patricia J Johnson Journal: Proc Natl Acad Sci U S A Date: 2014-05-19 Impact factor: 11.205
Authors: Ayesha B Alvero; Michele K Montagna; Vinicius Craveiro; Lanzhen Liu; Gil Mor Journal: Am J Reprod Immunol Date: 2011-09-14 Impact factor: 3.886
Authors: Andrea M Patterson; Saghar Kaabinejadian; Curtis P McMurtrey; Wilfried Bardet; Ken W Jackson; Rosemary E Zuna; Sanam Husain; Gregory P Adams; Glen MacDonald; Rachelle L Dillon; Harold Ames; Rico Buchli; Oriana E Hawkins; Jon A Weidanz; William H Hildebrand Journal: Mol Cancer Ther Date: 2015-12-30 Impact factor: 6.261
Authors: Lynn M Amon; Wendy Law; Matthew P Fitzgibbon; Jennifer A Gross; Kathy O'Briant; Amelia Peterson; Charles Drescher; Daniel B Martin; Martin McIntosh Journal: PLoS One Date: 2010-06-15 Impact factor: 3.240
Authors: Mathias Krockenberger; Yvonne Dombrowski; Claudia Weidler; Monika Ossadnik; Arnd Hönig; Sebastian Häusler; Heike Voigt; Jürgen C Becker; Lin Leng; Alexander Steinle; Michael Weller; Richard Bucala; Johannes Dietl; Jörg Wischhusen Journal: J Immunol Date: 2008-06-01 Impact factor: 5.422